Tagged Articles

long-term 37 articles

Analyst: diabetes drug sales expected to more than double by 2020

Sales of diabetes drugs should keep growing at about 10 percent a year for the rest of the decade, reaching $65 billion a year by 2020, says Jeffrey Holford, an analyst with Jefferies & Co. At that pace, diabetes drug revenues should more than double from the current $30 billion by the decade’s end. Holford says diabetes drug revenues should rise in relation to the aging population in the West, while in emerging markets, diabetes and obesity are increasing and access to health care is also growing. Other factors considered include higher drug prices, strong patent protection for key drugs, ... Read More

Patients with history of bladder cancer should avoid Actos altogether

Researchers have confirmed a link between a popular class of type 2 diabetes drugs and bladder cancer, Renal & Urology News reports. The drugs are in a class known as thiazolidinediones, which include the brand-name medications Avandia (rosiglitazone) and Actos (pioglitazone). The risk is even greater in patients who use Actos. “Consequently, pioglitazone (Actos) should be avoided in selected high-risk patients,” the medical publication warns. The findings come from a meta-analysis, published in the Canadian Medical Association Journal, aimed at determining the risk of bladder cancer among adults with type 2 diabetes taking this class of diabetes drugs. Type 2 ... Read More

Type 2 diabetes drug Actos now available in generic versions

The type 2 diabetes drug Actos (pioglitazone) is now available as a lower-costing generic. Actos is marketed by Japanese drug maker Takeda Pharmaceuticals. The patent for Actos expires in 2016; however, under the terms of a 2010 legal settlement, generic versions can be marketed as early as August 17, 2012. Both Ranbaxy Laboratories and Teva Pharmaceuticals are now selling generic Actos in three different doses. Another generic drug company, Watson Pharmaceuticals, had hoped to launch a generic version of Actos this week, but the Food and Drug Administration (FDA) has yet to grant the drug final approval. Last week, Watson ... Read More

Qsymia makers worry generics may take bite out of profits

Makers of the new obesity drug Qsymia have significantly scaled back their profit expectations after concerns that doctors may prescribe the drug’s ingredients separately rather than the drug itself. Vivus Inc., had estimated profits of as much as $3.6 billion per year, but scaled back its estimate to $1.2 billion, causing Vivus shares to tumble 7.7 percent earlier this week. Qsymia was one of two new long-term diet drugs approved by the Food and Drug Administration (FDA) earlier this year, making the drugs the first weight loss medications to be approved in 13 years. Qsymia was thought to be the ... Read More

New analysis shows diabetes, diabetes drug Actos, increase risk for bladder cancer

A new analysis of previously completed studies provides more evidence that people with type 2 diabetes have a greater risk of developing bladder cancer, and taking the diabetes drug Actos increases that risk even more. The study, published July 3 in the Canadian Medical Association Journal found that people with type 2 diabetes have a 40 percent increased risk of developing bladder cancer. This risk is believed to be associated with high levels of insulin. Insulin is also a growth hormone, and cancer cells have insulin receptors, which means they can use insulin to grow. Studies on type 2 diabetes ... Read More

FDA approves two life-long prescription diet drugs

Two new medications are the first in 13 years to be approved by the Food and Drug Administration (FDA) for long-term weight management. Marketed as Belviq and Qsymia, the prescription drugs are designed to be taken for the rest of a person’s life – along with a healthy lifestyle – for obese and overweight people who have been unsuccessful in getting their weight under control with diet and exercise. More than a third of adults in the United States are obese, and obesity contributes to a number of health conditions including high blood pressure, type 2 diabetes, and high cholesterol. “For ... Read More

Metformin may benefit non-diabetics with heart failure

The most commonly prescribed type 2 diabetes drug, metformin, has the potential to be developed into a new treatment for heart failure, according to a study funded by the British Heart Foundation. Research has already established that metformin can protect type 2 diabetics from cancer and cardiovascular disease, but a new study, led by Chim Lang, Professor of Cardiology at Dundee University in Scotland, shows that non-diabetics with heart failure may also benefit from the drug. Patients with heart failure are at risk for developing diabetes because their disease can lead to fatigue and shortness of breath, which can lead ... Read More

GSK to pay highest-ever award in Israeli court for concealing risks with diabetes drug

The highest-ever compensation in an Israeli class-action lawsuit against a drug manufacturer was awarded this week to a diabetes patient who claimed the company failed to disclose that its type 2 diabetes drug increased the risk of cardiovascular events. The lawsuit claimed that GlaxoSmithKline (GSK) concealed data from the public that showed its blockbuster drug Avandia increased the risk of dying of a heart attack. Under the compromise agreement, GSK was ordered to pay NIS 12.1 million – or $2.6 million. The award is expected to be used to fund a new treatment program for diabetics. In May 2007, the ... Read More

Diabetic retinopathy cases increase dramatically

The number of cases of a serious vision problem that affects diabetics is dramatically increasing, raising concerns among eye specialists. Diabetic retinopathy is damage to the blood vessels in the retina that occurs with long-term diabetes. It can lead to blindness. Approximately 8 million people ages 40 and older have diabetic retinopathy, up a startling 89 percent since 2000, according to the report issued by Prevent Blindness America. “We suspect that is largely due to the spike in diabetes and the diabetes epidemic we are facing as a country, as well as the increase in Hispanic and African-American populations, which ... Read More

Takeda stands behind type 2 diabetes drug Actos despite reports of bladder cancer

Takeda Pharmaceuticals says it is confident in its type 2 diabetes medication Actos despite studies that show the drug puts users at risk for bladder cancer. The drug company issued a statement following a newly published study that backed up bladder cancer risks brought to light in an earlier study. The new study involved data from more than 115,000 people who were treated with diabetes drugs from 1988 to 2009. Overall, 470 people were diagnosed with bladder cancer during about 4 ½ years of follow up. Diabetics treated with Actos had an 83 percent increased risk of bladder cancer than ... Read More